Gastric bypass surgery in NASH: a major modulator of hepatic mitochondrial dysfunction
Non-alcoholic fatty liver disease (NAFLD), the hepatic counterpart of metabolic syndrome, has gained increasing recognition worldwide as a component of the obesity and type 2 diabetes pandemic. The spectrum of NAFLD ranges from simple fatty liver with benign prognosis, to non-alcoholic steatohepatitis (NASH), which may progress to liver fibrosis and cirrhosis, thereby increasing morbidity and mortality. According to the traditional view, hepatic fat accumulation represents the prerequisite for hepatocyte injury to develop, whereas cytokines, adipokines, bacterial endotoxin, mitochondrial dysfunction and/or endoplasmic reticulum stress are described as aggravating factors involved in NASH progression. It is believed that approximately 1%–5% of the Western population exhibit NASH. However, no therapeutic approaches are currently effective in slowing or reversing NASH, and the most promising treatments remain weight loss and exercise. Generating rodent models for preclinical investigations on NASH has been quite challenging over the past years for several laboratories.1–3
Source: Gut - Category: Gastroenterology Authors: Baraille, F., Guilmeau, S., Postic, C. Tags: Commentary Source Type: research
More News: Alcoholism | Cirrhosis | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Gastric Bypass | Gastroenterology | Liver | Liver Disease | Metabolic Syndrome | Mitochondrial Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Pandemics | Sports Medicine | Urology & Nephrology | Weight Loss